The NM_000232.5(SGCB): c.341C>T variant in SGCB is a missense variant predicted to cause substitution of serine by phenylalanine at amino acid 114, p.(Ser114Phe). This variant has been detected in at least 29 individuals with limb girdle muscular dystrophy. Of those individuals, five had a likely pathogenic variant in unconfirmed phase (c.31C>T p.(Gln11Ter), 0.25 pts x5, PMIDs: 32875335, 30919934). Another 24 individuals were homozygous for the variant (1 pt, PMIDs: 25862795, 29970176, 25135358, 20071171, 30919934, 18996010, 26404900, 18285821, 9032047, 10942431) (PM3_Strong). The variant has been reported to segregate with autosomal recessive limb-girdle muscular dystrophy in two pairs of affected siblings from two families (PP1_Moderate; PMIDs: 30919934, 20071171). At least one patient homozygous for this variant displayed progressive limb girdle muscle weakness and absent beta-sarcoglycan protein expression, which is highly specific for SGCB-related LGMD (PMID: 10942431; PP4_Moderate) (capped with PP1_Moderate). An in vitro assay in a heterologous cell system has demonstrated that this variant disrupts membrane localization of the sarcoglycan complex (PMID: 37317968; PS3_Moderate). The computational predictor REVEL gives a score of 0.855, which is above the threshold of 0.7, evidence that correlates with impact to SGCB function (PP3). The upper bound of the 95% confidence interval of the Grpmax variant allele frequency in gnomAD v4.1.1 (725/1179486 European (non-Finnish) chromosomes), which is higher than the LGMD VCEP threshold (<0.00009) for PM2_Supporting, and therefore does not meet this criterion. In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive limb-girdle muscular dystrophy based on the ACMG/AMP criteria applied, as specified by the ClinGen LGMD VCEP (specifications version v2.0.0; 04/29/2026): PM3_Strong, PS3_Moderate, PP1_Moderate, PP4_Moderate, PP3.